10.1038/s41598-020-75621-5 Summary Keywords incretinbased therapy, GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), T2D (type 2 diabetes), obesity, incretin receptors Citation Austin GO and Tomas A (2023) Variation in responses to incretin therapy: Modifiable and non-modifiable factors
This is a recognized cause of altered breath odor, especially during periods of rapid weight loss
Neither is definitively better
They eat different diets, have different gut transit times, and harbor different bacterial species
Lastly, it also boosts immune function and reduces inflammation, all things linked to an increased healthspan
A valid stability-indicating method must: Resolve the main peptide from all degradation products Detect impurities at low regulatory thresholds Accurately quantify impurities even in stressed samples Forced degradation samples are therefore essential during method development and validation for GLP-1 peptide drugs